Results 31 to 40 of about 27,411 (201)

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +2 more sources

Meta-analysis on the effects of octreotide on tumor mass in acromegaly. [PDF]

open access: yesPLoS ONE, 2012
BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Andrea Giustina   +5 more
doaj   +1 more source

Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China

open access: yesPediatric Investigation, 2020
Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present
Bingyan Cao   +8 more
doaj   +1 more source

Octreotide Use in Neonates:A Case Series [PDF]

open access: yes, 2018
Background and Objective: Octreotide is a somatostatin analogue and has been used off-label for a variety of conditions. There are no specific guidelines for the use of octreotide in neonates and its safety and efficacy have not been systematically ...
Syed Ahmed Zaki   +5 more
core   +1 more source

Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature

open access: yesCase Reports in Gastrointestinal Medicine, 2019
We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of ...
Matthew H. Kemm   +4 more
doaj   +1 more source

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

open access: yesCellular Physiology and Biochemistry, 2018
Background/Aims: Hepatocellular carcinoma (HCC) is a major threat to human health. The condition carries a high risk of death; 45% of new cases occur in China.
Chuan-Zhong Huang   +5 more
doaj   +1 more source

TARGETING PEPTIDES CONTAINING SUPRAMOLECULAR AGGREGATES TOWARD CANCER CELLS [PDF]

open access: yes, 2009
Multimodal supramolecular compounds that combine imaging and therapeutic capabilities are the focus of intensive research for applications in the growing field of nanomedicine.
Morisco, Anna
core   +1 more source

Octreotide acetate enhanced radio sensitivity and induced apoptosis in MCF7 breast cancer cell line

open access: yesJournal of Radiation Research and Applied Sciences, 2022
Introduction: Breast cancer is the most common type of cancer among women. Radiotherapy is one of the treatment options for breast cancer; it plays a significant role in tumour control after surgery. However, radio resistance developed by tumour cells is
Alkhansa Salih Mahmoud   +4 more
doaj   +1 more source

Octreotide may improve pharyngocutaneous fistula healing through downregulation of cystatins: A pilot study

open access: yesLaryngoscope Investigative Otolaryngology, 2023
Background Pharyngocutaneous fistula (PCF) and salivary leaks are well known complications of head and neck surgery. The medical management of PCF has included the use of octreotide without a well‐defined understanding of its therapeutic mechanism.
Jonathan Cohen   +7 more
doaj   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

open access: yesMolecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy